Abstract
Concerns are increasing that the drugs we have used to treat this chronic pulmonary infection will cease to work because of development of resistance, raising the threat of untreatable disease. This review explains the molecular and clinical basis of resistance. The current best practice for the treatment of multi-drug resistance is described. There are a number of new drugs and regimens currently under investigation and these are described. The importance of improved case finding, diagnosis and early treatment are emphasised.
| Original language | English |
|---|---|
| Pages (from-to) | 211-216 |
| Number of pages | 6 |
| Journal | Current Respiratory Medicine Reviews |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 27 Nov 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antibiotic resistance
- Drug treatment
- Extremely drug resistant
- Multidrug resistance
- Tuberculosis
Fingerprint
Dive into the research topics of 'MDR/XDRTB: What are the new treatment options?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver